Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The U.K.'s NICE recommended the use of Xolair omalizumab on the National Health Service (NHS) as an
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury